Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin injection site optimization for chronic anal fissure
NL-OMON20571Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of neuronox in chronic anal fissure (CAF) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Treatment efficacy. Planned start Sep 2020; status: not yet recruiting.
02
Drugs
neuronox
03
Conditions
chronic anal fissure (CAF)
Beyond the preview
Go deeper on NL-OMON20571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON20571.